Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Men more likely to abandon partners diagnosed with cancer

A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

10 Nov 2009

Teenage women who are obese at higher risk to develop MS as adults

Teenage women who are obese may be more than twice as likely to develop multiple sclerosis (MS) as adults compared to female teens who are not obese, according to a study published in the November 10, 2009, print issue of Neurology-, the medical journal of the American Academy of Neurology.

10 Nov 2009

Children with autism may have lower quality handwriting, says study

Children with autism may have lower quality handwriting and trouble forming letters compared to children without autism, according to a study published in the November 10, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

9 Nov 2009

Daval International receives award for its anti-inflammatory agent AIMSPRO

Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

9 Nov 2009

PPA bus tour raises awareness of patient assistance programs among state residents who are uninsured

The 'Help is Here Express' bus tour will be stopping in South Carolina and Georgia throughout the week of November 9-13 at various cities in order to help uninsured and financially-struggling patients access information on programs that provide prescription medicines for free or nearly free.

7 Nov 2009

Seminar highlights the importance of chronic health issues

With 125 million Americans challenged by at least one chronic illness and 22% of that number facing life with two or more chronic illnesses, early, smart estate and financial planning can make the difference between maximizing control over your life or falling victim to its exigencies.

7 Nov 2009

National Institutes of Health grants $6-million for brain disease research

Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

People with MS who relapse within first five years of onset have more severe disability: Study

People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.

5 Nov 2009

EFOF's initative to raise epilepsy awareness

Each year, some 50,000 Americans die from seizures and related causes, triggering more deaths annually than breast cancer. The Epilepsy Foundation of Florida (EFOF) is working to educate the public about this condition during November, Epilepsy Awareness Month.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009.

3 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009